Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > I see no ratbar99

<< Previous

Bullboard Posts

Next >>

Comment by nobeardon Oct 05, 2021 12:32pm

154 Views

Post# 33967361

RE:I see no ratbar99

https://ca.video.search.yahoo.com/video/play;_ylt=AwrWq7n1fVxhl1YA4AyU7olQ;_ylu=c2VjA3NyBHNsawN2aWQEdnRpZAMEZ3BvcwM3?p=babar+in+a+car&vid=fbf1b58ceb69d2081397dfe829874df1&turl=https%3A%2F%2Ftse1.mm.bing.net%2Fth%3Fid%3DOVP.FkNBxMtalS7wowi1yUS52QEsDh%26pid%3DApi%26h%3D225%26w%3D300%26c%3D7%26rs%3D1&rurl=https%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3D1ndI1NPhanQ&tit=Meet+Babar+and+His+Family&c=6&h=225&w=300&l=323&sigr=JpAdBCqPxtlt&sigt=Od8tJE2zfOsW&sigi=BskmesOTtEko&age=1584922978&fr2=p%3As%2Cv%3Av&fr=yfp-hrmob&tt=b